Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERIBEL: Eribulin in HER2-negative MBC
NCT02061085Phase 2Completed
- Sponsor
- MEDSIR
- Start
- Jul 2013
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eribulin in breast cancer, sponsored by MEDSIR. Primary endpoint: Time to Progression at 27 months. Started Jul 2013; status: completed.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02061085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02061085.